一款已在国内上市的国产新冠口服药，有望成为应对致死率高达70%尼帕病毒的武器。 近期，中国科学院武汉病毒研究所（以下简称"武汉病毒所"）等机构的研究团队在国际期刊《新兴微生物与感染》上发表了一项重要成果，证实已上市的口 服新冠药VV116（民得维）对尼帕病毒具有显著的抗病毒活性。 尼帕病毒被世界卫生组织（WHO）列为最高优先级的区域性威胁，其宿主范围广、致死率高，且目前全球尚无获批的特效药物或疫苗。最新研究的动物实 验显示，口服VV116能将受感染金黄地鼠的存活率提升至66.7%，并显著降低其关键器官中的病毒载量，这为应对潜在的尼帕病毒疫情提供了一个"现成的药 物选择"。 最新研究证实：VV116对高致死率尼帕病毒有显著抑制作用 一款已经成功用于治疗新冠的药物，如今在另一种更为致命的病毒面前展现了潜力。 1月26日晚间，武汉病毒所发布文章表示，近期，中国科学院武汉病毒研究所肖庚富/张磊砢研究员团队、单超研究员团队联合上海药物研究所等在国际期刊 Emerging Microbes & Infections上发表了题为"The oral nucleoside drug VV116 is a promising c ...

智通财经记者 | 陈杨 智通财经编辑 | 许悦 日前，印度东部西孟加拉邦出现的尼帕病毒病疫情引发广泛关注。 据新华社1月26日援引外媒消息，当地有5例确诊病例，其中包括医护人员。近100人已被要求居家隔 离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中一名患者病情危重。 另据央视新闻记者1月27日从国家疾控局了解到，此次印度尼帕病毒病疫情对中国产生的影响相对较 小。目前，中国尚未发现尼帕病毒病病例。但也存在一定境外输入风险，需加强防范。 实际上，尼帕病毒并非当下新发现的病毒。据中国疾控中心2021年发布的《尼帕病毒病预防控制技术指 南》（下称《技术指南》），1998年，马来西亚首次发生尼帕病毒病暴发疫情。1999年3月，马来西亚 病毒学家从来自尼帕村的患者样本中分离出该种病毒，命名为尼帕病毒。 正是因为尼帕病毒传播性不高，相应药物商业价值有限，当下尚无针对尼帕病毒的抗病毒药物和疫苗研 发出来、获批上市。《技术指南》仅提及，利巴韦林对治疗尼帕病毒脑炎可能有效。该药是一种临床上 常见的广谱抗病毒药物。 目前，全球尼帕病毒病疫情主要发生在南亚和东南亚国家。其自然宿主为果蝠，主要分布在南亚、东南 亚和澳大利亚。 ...

Core Viewpoint - Real Bio Technology Co., Ltd. is facing significant financial challenges as it seeks to go public on the Hong Kong Stock Exchange, with a cumulative loss of nearly 1 billion yuan over two and a half years due to declining sales and the termination of a partnership with Fosun Pharma [1][2][5]. Financial Performance - The company reported a cumulative loss of 989 million yuan over the past two and a half years, with net profits of -784 million yuan in 2023, -40.04 million yuan in 2024, and -165 million yuan in the first half of 2025 [3][4]. - Revenue peaked at over 1 billion yuan in 2022 but plummeted to 238 million yuan in 2024, with a staggering 91.65% year-on-year decline in the first half of 2025, generating only 16.53 million yuan [2][3]. Product and Market Challenges - Real Bio's only commercialized product, Azvudine, achieved significant sales initially but has seen demand shrink, leading to a heavy reliance on a single client, Fosun Pharma, which accounted for 99.2% of its revenue in 2024 [2][4]. - Following the termination of the partnership with Fosun Pharma, the company struggled to establish new distribution agreements, resulting in only 1.37 million yuan in revenue from Azvudine sales in 2024 [2][4]. Research and Development - The company is attempting to diversify its product pipeline by exploring new indications for Azvudine and developing combination therapies, but R&D expenditures have decreased from 238 million yuan in 2023 to 151 million yuan in 2024, indicating financial constraints [4][5]. - Current clinical trials for new indications are in early stages, and the potential for revenue generation from these efforts remains uncertain in the short term [4]. Financial Pressures and Future Outlook - Real Bio faces significant financial pressure, with cash and cash equivalents of only 50.05 million yuan against administrative and R&D expenses nearing 100 million yuan [4][5]. - The company is also burdened by redemption clauses from previous financing rounds, which could exacerbate its financial difficulties if performance does not improve [5]. - Analysts suggest that the company's future hinges on its ability to leverage IPO funds to alleviate debt and demonstrate the potential value of its R&D pipeline [5].

Core Viewpoint - Real Bio Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, facing significant financial challenges due to declining revenues and high losses, primarily linked to its dependence on a single product, Azvudine [1][3][6]. Financial Performance - The company reported a cumulative loss of 989 million RMB over two and a half years, with net losses of 784 million RMB in 2023, 40 million RMB in 2024, and 165 million RMB in the first half of 2025 [4][6]. - Revenue peaked at over 1 billion RMB in 2022 but plummeted to 344 million RMB in 2023 and is projected to drop to 238 million RMB in 2024, with a staggering 91.65% decline in the first half of 2025, resulting in only 16.53 million RMB [2][3][4]. Product and Market Dependency - Azvudine is the only commercialized product, which has faced a significant drop in demand following the termination of its partnership with Fosun Pharma, leading to a highly concentrated customer base where 99.6% of revenue came from the top five clients in 2024 [3][4]. - The company is attempting to diversify its product offerings by exploring new indications for Azvudine and developing additional drug candidates, including CL-197 for HIV and other oncology treatments [6][7]. Research and Development Challenges - Despite efforts to expand its R&D pipeline, the company has seen a 36.8% decrease in R&D spending from 2.38 billion RMB in 2023 to 1.51 billion RMB in 2024, which raises concerns about its ability to innovate and generate future revenue [6][7]. - The current R&D projects are primarily in early clinical stages, which may not yield immediate financial returns, complicating the company's transition from a single-product focus to a diversified pharmaceutical entity [6][7]. Financial Obligations and Pressure - Real Bio is under pressure from a total of 713 million RMB in financing agreements with redemption clauses, which could force the company to buy back preferred shares at a 10% annual interest rate if certain conditions are met [1][7]. - As of mid-2025, the company had only 50.05 million RMB in cash, while administrative and R&D expenses approached 100 million RMB, indicating a significant cash flow issue [7].

Core Viewpoint - The article discusses the significant breakthrough in spinal cord injury (SCI) treatment through the discovery of Thiorphan, a drug that promotes neuronal regeneration and functional recovery after SCI, offering new hope for patients suffering from paralysis and disability [2][3][6]. Group 1: Research Findings - A study published in Nature identified Thiorphan as a candidate drug that reprograms neurons to enhance recovery after spinal cord injury [3]. - Thiorphan, originally developed as a neutral endopeptidase inhibitor for treating diarrhea, has shown remarkable potential in promoting nerve regeneration and functional recovery in SCI models [11][19]. - In experiments with adult mice, Thiorphan increased total neurite growth by 80% and the longest neurite length by 30%, demonstrating a dose-dependent effect [12]. Group 2: Experimental Validation - In a rat model of severe cervical spinal cord injury, treatment with Thiorphan initiated two weeks post-injury resulted in a twofold increase in forelimb grasp success rate, improving accuracy from 30% to 60% when combined with neural stem cell transplantation [14]. - Anatomical evidence indicated that Thiorphan treatment led to a 60% increase in the regeneration of corticospinal axons, establishing synaptic connections across the injury site [15]. - Thiorphan was also effective in promoting growth in cortical neurons from both adult macaques and a 56-year-old human, with increases of 30.3% in total neurite growth and 23% in the longest neurite length [16]. Group 3: Mechanism of Action - The mechanism of Thiorphan involves upregulating brain-derived neurotrophic factor (BDNF) and phosphorylated AKT, allowing neurons to revert to a developmental state and regain growth capabilities [17]. - Given that Thiorphan has been safely used in humans, the clinical development risk is significantly reduced [19]. Group 4: Future Directions - The research team is exploring more convenient administration methods, including intrathecal injection or systemic delivery, and developing derivatives with better blood-brain barrier permeability [20]. - This study not only identifies a promising candidate for SCI treatment but also establishes a new paradigm for drug development from computer screening to human validation, which could be applied to other neurological and neurodegenerative diseases [20].

Core Insights - The article discusses a significant breakthrough in the treatment of Rett Syndrome, a rare genetic disorder caused by mutations in the MeCP2 gene, primarily affecting girls at a rate of 1 in 10,000 [6] - Researchers at Harvard's Wyss Institute have identified Vorinostat, an FDA-approved drug for skin T-cell lymphoma, as a promising therapeutic option for Rett Syndrome, demonstrating disease-repair capabilities in preclinical models [2][8] Rett Syndrome Challenges - Rett Syndrome is characterized by complex cognitive and physical impairments due to a single gene mutation, leading to multiple organ dysfunctions, including neurological, digestive, muscular, and immune system issues [6] - The complexity of the disease, involving changes in multiple gene expressions, complicates the development of effective treatments based on single drug targets [6] Research Methodology - The research team utilized an AI-driven system called nemoCAD to revolutionize traditional drug development approaches by: 1. Constructing animal models using African clawed frog tadpoles to simulate human MeCP2 gene mutations, replicating various symptoms of Rett Syndrome [7] 2. Conducting whole-genome analysis to compare gene expression changes between healthy and affected tadpoles [7] 3. Performing drug reverse screening based on gene expression profiles from the NIH LINCS database to identify candidate drugs that could reverse pathological changes [7] Drug Discovery and Results - Vorinostat, a histone deacetylase inhibitor, showed the most promising results, significantly reversing abnormalities in neurological, intestinal, and muscular systems in affected tadpoles [8] - The research indicates that Vorinostat could potentially be the first curative therapy for Rett Syndrome, leveraging a unique AI-based drug discovery approach combined with innovative disease modeling [11] Clinical Trials and Future Plans - Unravel Biosciences, a biotech company incubated by Wyss Institute, plans to initiate clinical trials in Colombia in 2025, involving 15 female patients [12] - The trials will adopt an n-of-1 personalized experimental design, adjusting treatment plans for each patient, and will advance the proprietary formulation RVL-001 of Vorinostat [12]

Core Viewpoint - The innovative drug sector in the A-share market has seen significant stock price increases, with several leading companies achieving over 100% growth in 2023, driven by breakthroughs in new drug development [1] Group 1: Company Developments - Shuyou Shen's investigational drug for hemophilia has received breakthrough therapy designation and has submitted a conditional marketing application [1] - Taiankang's innovative drug CKBA ointment has been recognized for its research published in the top immunology journal, Immunity, highlighting its potential in treating vitiligo [1][2] - The research team led by Wang Honglin at Shanghai Jiao Tong University has identified a novel pathogenic mechanism in vitiligo involving sensory neurons and CGRP, which could lead to new treatment strategies [6][7] Group 2: Clinical Trials and Research Findings - The study revealed that blocking the CGRP receptor with Rimegepant significantly inhibits disease progression in vitiligo mouse models and shows promising results in a clinical trial with 57 patients [2][8] - The ongoing Phase II clinical trial for CKBA ointment aims to evaluate its safety and efficacy in non-segmental vitiligo patients, with results expected in July 2023 [11] - The research indicates that CKBA ointment can effectively suppress autoreactive CD8+ T cells, offering a differentiated approach compared to existing treatments [12] Group 3: Market Potential - The global prevalence of vitiligo is estimated at 0.5% to 2%, with approximately 30 million patients in China, indicating a substantial market opportunity for effective treatments [9][12] - The potential market for innovative vitiligo drugs in China is projected to exceed 20 billion yuan, highlighting the demand for targeted therapies [12] - Despite the approval of Ruxolitinib for vitiligo, its market share remains limited, underscoring the need for new therapies to meet patient needs [12]